scholarly journals Clinical and Therapeutic Trial for the Efficacy of Narrow Band - UVB Phototherapy versus Systemic Therapy in Moderate and Severe Atopic Dermatitis of the Adult

2018 ◽  
Vol 64 (1) ◽  
pp. 17-21
Author(s):  
Gyula Laszlo Fekete ◽  
László Fekete
Keyword(s):  
Atopic Dermatitis ◽  
Side Effects ◽  
Systemic Therapy ◽  
Systemic Corticosteroid ◽  
Corticosteroid Treatment ◽  
Serum Levels ◽  
Severe Atopic Dermatitis ◽  
Therapeutic Trial ◽  
Group I ◽  
Uvb Phototherapy

AbstractObjectives: The aim of this clinical and therapy study was to evaluate the efficacy of NB-UVB phototherapy versus systemic therapy in moderate-to-severe atopic dermatitis of the adult.Material and methods: The subjects of the study were divided into two groups of 25 adult patients with moderate and severe atopic dermatitis according to the inclusion criteria. The first group of 25 patients were treated with systemic corticosteroids while the second group of 25 patients were treated with NB-UVB phototherapy. At the end of the study, after all the data were centralized, we performed a statistical analysis of the results, comparing the two groups as well as the efficacy of the different therapies.Results: In group I the clinical efficacy of the systemic corticosteroid treatment was achieved, on average, at 4 weeks in patients with moderate atopic dermatitis and at 6 weeks in patients with severe atopic dermatitis. In group II the clinical effecacy of NB-UVB phototherapy was achieved, on average, at 6 weeks for patients with moderate atopic dermatitis and at 8 weeks for those with the severe form. In both groups, the total IgE serum levels were elevated at the beginning, and they became normal throughout the clinical improvement. Remarkable therapy-related side effects were found in the first study group.Conclusion: We conclude that NB-UVB phototherapy had similar efficacy in treating moderate-to-severe atopic dermatitis with minimal side effects compared to systemic corticosteroid therapy.

scholarly journals Long-wavelength ultraviolet A (UVA-1) phototherapy for the treatment of patients with atopic dermatitis

2021 ◽  
Vol 97 (5) ◽  
pp. 26-37
Author(s):  
A. E. Karamova ◽  
V. V. Chikin ◽  
A. A. Kubanov ◽  
L. K. Davletbaeva
Keyword(s):  
Atopic Dermatitis ◽  
Drug Therapy ◽  
Side Effects ◽  
Radiation Dose ◽  
Mechanisms Of Action ◽  
Severe Atopic Dermatitis ◽  
Ultraviolet A ◽  
Long Wavelength ◽  
Discontinuation Of Treatment ◽  
Skin Phototype

One of the methods of therapy for atopic dermatitis is long-wavelength ultraviolet therapy A (UVA-1- therapy). This review aims to provide the mechanisms of action of UVA-1-therapy an overview about the effectiveness of UVA-1-therapy in patients with atopic dermatitis taking into account factors that can affect the effectiveness of treatment radiation dose, skin phototype of patients, concomitant drug therapy. The available data on a decrease in the severity of atopic dermatitis as a result of the course of UVA-1-therapy and on a decrease in the severity of itching in patients are presented. The data on the rate of onset of the therapeutic effect of UVA-1-therapy and the duration of its maintenance are considered. The safety of UVA-1-therapy is discussed, and the most frequent undesirable effects a feeling of warmth, fever, itching, hyperpigmentation, are given. The possibility of developing side effects requiring discontinuation of treatment is assessed. The data obtained indicate the effectiveness and safety of the UFA-1-radiation in the treatment of patients with moderate-to-severe atopic dermatitis.

Marfan syndrome in combination with severe atopic dermatitis: importance of early diagnosis and treatment of patients with allergic dermatitis in childhood

2021 ◽  
Vol 16 (2) ◽  
pp. 68-73
Author(s):  
P.G. Svist ◽  
◽  
E.V. Orlova ◽  
L.M. Smirnova ◽  
S.S. Parshintseva ◽  
...  
Keyword(s):  
Early Childhood ◽  
Atopic Dermatitis ◽  
Side Effects ◽  
Marfan Syndrome ◽  
Clinical Manifestations ◽  
Treatment Strategies ◽  
Hereditary Diseases ◽  
Severe Atopic Dermatitis ◽  
Key Words Atopic Dermatitis ◽  
Effective Treatment Regimen

We report a case of a rare combination of Marfan syndrome and severe atopic dermatitis (AD) in a 32-year-old male patient. He developed AD in early childhood and then had a relapse at the age of 18 years caused by stress. After this, AD became severe due to stress associated with aortic aneurysmectomy. The patient also had side effects caused by steroids, including multiple pustular eruptions, Kaposi's varicelliform eruption, edema and hyperemia of the periorbital area, pain and swelling of the small joints of the hands. These side effects, as well as specific cardiovascular symptoms typical of Marfan syndrome necessitated the search for alternative treatment strategies for severe AD. Eventually, we managed to find an effective treatment regimen that caused no side effects or adverse events, while the symptoms subsided. This case demonstrates the importance of early AD diagnosis in childhood in order to prevent its transition into severe chronic form that can hardly be managed in adulthood. Key words: atopic dermatitis, children, diagnostic criteria, clinical manifestations, hereditary diseases, Marfan syndrome

Diagnosis of Multiple Inhalant Allergies in Children by Radioimmunoassay

PEDIATRICS ◽  
1974 ◽  
Vol 54 (2) ◽  
pp. 151-156
Author(s):  
Donald R. Hoffman ◽  
Zack H. Haddad
Keyword(s):  
Atopic Dermatitis ◽  
House Dust ◽  
Skin Testing ◽  
Skin Tests ◽  
Severe Atopic Dermatitis ◽  
Group I ◽  
Wide Range ◽  
Radioallergosorbent Test ◽  
Inhalant Allergens ◽  
Inhalant Allergy

A series of 302 patients reporting immediate hypersensitivity symptoms to inhalant allergens was evaluated by both puncture skin testing and the radioallergosorbent test (RAST) using 13 common inhalant allergens. Agreement between the two tests varied from 71% to 93% for the various allergens and averaged 82%. The best correlation, 93%, was obtained with mixed grass pollen allergens. If a purified allergen, rye group I, was used the correlation rose to 97.5%. The correlation was 88% for the mold Alternaria, and the negative-sera did not become positive when tested over a wide range of dilutions. Fifty-eight percent of the patients with house dust allergy reacted to house dust mite (Dermatophagoides farinae). Correlations of 71% to 93% were obtained with ten weed and tree pollens. The only patients in whom positive RASTs were found with negative skin tests to the same antigen had either severe atopic dermatitis or decreased skin response to exogenous histamine. Sera from a group of 20 patients with positive allergy history but negative skin tests also had negative RAST. The radioallergosorbent test appears to add little information to that obtained by a comprehensive allergy history and puncture skin tests in the great majority of children with inhalant allergy. The only exceptions were children with severe atopic dermatitis, suppressed skin reactivity or dermatographism.

Narrow-band UVB phototherapy for severe atopic dermatitis

1996 ◽  
Vol 135 (2) ◽  
pp. 332-332 ◽  
Author(s):  
M. J. Hudson-Peacock ◽  
B.L. Diffey ◽  
P. M. Farr
Keyword(s):  
Atopic Dermatitis ◽  
Narrow Band ◽  
Severe Atopic Dermatitis ◽  
Uvb Phototherapy

A Short Cycle of Narrow-Band UVB Phototherapy in the Early Phase of Dupilumab Therapy Can Provide a Quicker Improvement of Severe Atopic Dermatitis

Dermatology ◽  
2021 ◽  
pp. 1-9
Author(s):  
Mariateresa Rossi ◽  
Chiara Rovati ◽  
Mariachiara Arisi ◽  
Cesare Tomasi ◽  
Irene Calzavara-Pinton ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Narrow Band ◽  
Ultraviolet B ◽  
Adult Patients ◽  
Severe Atopic Dermatitis ◽  
Treatment Regimens ◽  
Short Course ◽  
Receive Treatment ◽  
Uvb Phototherapy

<b><i>Background:</i></b> Since the best clinical response to dupilumab is achieved after 12–16 weeks, a combination therapy at the beginning of the treatment could be a helpful strategy to reach a faster response in patients with severe atopic dermatitis (AD). <b><i>Objectives:</i></b> To quantify the benefit of a combination of dupilumab treatment with a short course of narrow-band ultraviolet B (NB-UVB) phototherapy. <b><i>Methods:</i></b> In the present pilot study adult patients suffering from severe AD were enrolled with a 2:1 ratio to receive treatment with dupilumab alone or dupilumab plus NB-UVB phototherapy, for 12 weeks. After the twelfth week, all patients received dupilumab only. A follow-up visit took place after 16 weeks. Both clinician-oriented and patient-oriented scores were assessed at baseline (T0) and after 4 (T1), 12 (T2) and 16 (T3) weeks. <b><i>Results:</i></b> Forty-five adult patients were enrolled in the study. Both treatment regimens were well tolerated and very effective on all measured scores (EASI, SCORAD, BSA, NRS of itching, NRS of sleep loss, DLQI, POEM and HADS), but the combined regimen led to a more robust clinical improvement of lesions and relief of symptoms after 4 weeks. However, after 12 and 16 weeks, the additional therapeutic effect of phototherapy weakened. <b><i>Conclusion:</i></b> NB-UVB phototherapy can provide a faster remission of severe AD in the first few weeks of dupilumab therapy.

Protein-losing enteropathy in an infant with severe atopic dermatitis

2021 ◽  
Vol 14 (4) ◽  
pp. e241057
Author(s):  
Yuji Fujita ◽  
Kohei Nomura ◽  
Shigemi Yoshihara
Keyword(s):  
Atopic Dermatitis ◽  
Serum Albumin ◽  
Topical Corticosteroid ◽  
Urine Volume ◽  
Male Infant ◽  
Corticosteroid Treatment ◽  
Severe Atopic Dermatitis ◽  
Protein Losing Enteropathy ◽  
Protein Levels ◽  
Recurrent Vomiting

Severe atopic dermatitis (AD) may lead to various complications such as hypoproteinaemia. We describe the case of a 7-month-old male infant with severe AD complicated with protein-losing enteropathy (PLE). He was diagnosed with AD at 2 months of age; however, because of familial steroid phobia, topical corticosteroids were not administered. At 7 months of age, he was admitted to our hospital for decreased feeding, diarrhoea, reduced urine volume and recurrent vomiting. Class 3 topical corticosteroid treatment was initiated. On day 3, eczema had almost resolved. However, serum protein levels had not improved; oliguria persisted and oedema worsened. Serum albumin scintigraphy revealed radioisotopes in the distal duodenum, leading to PLE diagnosis. Systemic prednisolone and albumin were administered, with no PLE relapse after discontinuation. To our knowledge, only two infant PLE cases associated with AD were reported to date. PLE should be considered in patients with severe AD and persistent hypoproteinaemia.

Hydrocortisone 17-Butyrate (Locoid®) 0.1% Fatty Cream versus Desonide (Apolar®) 0·1% Ointment in the Treatment of Patients Suffering from Atopic Dermatitis

1986 ◽  
Vol 14 (2) ◽  
pp. 85-90 ◽  
Author(s):  
G Rajka ◽  
H L Veijans
Keyword(s):  
Atopic Dermatitis ◽  
Side Effects ◽  
Skin Diseases ◽  
Skin Lesions ◽  
Severe Atopic Dermatitis ◽  
Double Blind ◽  
Application Form ◽  
Wide Range ◽  
Ointment Formulation ◽  
Efficacy Of Treatment

A randomized, double-blind, left-right study to compare the therapeutic efficacy and the cosmetic acceptability of the new hydrocortisone 17-butyrate (Locoid®) 0·1% fatty cream application form with desonide (Apolar®) 0·1% ointment was performed in thirty patients suffering from moderate to severe atopic dermatitis. The medications were applied to symmetrical, bilateral skin lesions twice daily for 4 weeks. Both treatments effected highly significant reductions of the score values for the severity of all clinical skin parameters assessed. Score reductions were, however, more pronounced on Locoid-treated sides than on Apolar-treated sides both after 2 and 4 weeks of therapy. It appeared further that clinical efficacy of treatment at completion of the study was also in favour of Locoid-treated sides, indicating that Locoid fatty cream is more effective than Apolar ointment. No serious side-effects were reported during the study. The expressed patient preferences with respect to cosmetic acceptability of treatments were significantly in favour of Locoid fatty cream, indicating that patients preferred the use of this new galenic formulation over an ointment formulation. It is concluded that the new application form of Locoid, a fatty cream, is a useful and beneficial addition to topical corticosteroid therapy, which will promote patient compliance in a wide range of corticosteroid-responsive skin diseases.

Sign in / Sign up

Export Citation Format

Share Document